師資
個(gè)人簡(jiǎn)介：
盧奕，博士，現(xiàn)為南方科技大學(xué)研究副教授，博士生導(dǎo)師。美國(guó)腫瘤研究學(xué)會(huì)會(huì)員、美國(guó)骨及礦物質(zhì)研究學(xué)會(huì)會(huì)員、中國(guó)免疫學(xué)會(huì)終身會(huì)員、中國(guó)生物醫(yī)學(xué)技術(shù)協(xié)會(huì)轉(zhuǎn)化醫(yī)學(xué)分會(huì)理事、中國(guó)抗癌協(xié)會(huì)腫瘤轉(zhuǎn)移專業(yè)委員會(huì)委員、腫瘤微環(huán)境專業(yè)委員會(huì)委員。自2002年起至2011年初回國(guó)前在美國(guó)密西根大學(xué)和匹茲堡大學(xué)腫瘤中心做博士后和研究員。作為研究骨干參與完成多項(xiàng)美國(guó)DOD和NIH研究項(xiàng)目。回國(guó)后，曾任廣西南寧市特聘教授；廣西醫(yī)科大學(xué)轉(zhuǎn)化醫(yī)學(xué)研究中心副主任、教授、博士生導(dǎo)師；長(zhǎng)壽與老年相關(guān)疾病教育部重點(diǎn)實(shí)驗(yàn)室副主任。作為項(xiàng)目主持人，主持多項(xiàng)國(guó)家及省部級(jí)科研項(xiàng)目，2011年，2012年，2017年和2019年多次獲得國(guó)家自然科學(xué)基金面上項(xiàng)目；2012年獲得廣西自然基金回國(guó)重點(diǎn)項(xiàng)目和教育廳重點(diǎn)項(xiàng)目各1項(xiàng)；2017年獲得深圳市科創(chuàng)委學(xué)科布局項(xiàng)目1項(xiàng)和自由探索項(xiàng)目1項(xiàng)。已完成國(guó)家973重大科學(xué)研究項(xiàng)目子課題1項(xiàng)（排名第二），主持并完成天津市應(yīng)用基礎(chǔ)研究重點(diǎn)項(xiàng)目1項(xiàng)，國(guó)自然面上項(xiàng)目2項(xiàng)。作為第二負(fù)責(zé)人參加國(guó)家自然科學(xué)基金重點(diǎn)項(xiàng)目研究1項(xiàng)；廣西壯族自治區(qū)重大研究項(xiàng)目1項(xiàng)以及平臺(tái)建設(shè)項(xiàng)目多項(xiàng)。擔(dān)任NSFC評(píng)審委員。研究成果多次獲獎(jiǎng)，2007年獲得美國(guó)骨疾病研究學(xué)會(huì)頒發(fā)的青年學(xué)者獎(jiǎng)，并多次獲得省部級(jí)科技進(jìn)步獎(jiǎng)。多年主講本科生《醫(yī)學(xué)免疫學(xué)》、《分子生物學(xué)》、《臨床免疫及診斷》，研究生《分子生物學(xué)進(jìn)展》、《高級(jí)免疫學(xué)》。指導(dǎo)和培養(yǎng)博士研究生6名，碩士研究生12名。發(fā)表論文70余篇，其中SCI收錄論文60篇。近五年以第一作者和/或通訊作者發(fā)表研究論文15篇。擁有美國(guó)發(fā)明專利1項(xiàng)，已授權(quán)中國(guó)專利3項(xiàng)。研究方向：腫瘤微環(huán)境與腫瘤轉(zhuǎn)移、腫瘤血管形成與腫瘤免疫。
研究領(lǐng)域：
腫瘤微環(huán)境與腫瘤轉(zhuǎn)移
腫瘤預(yù)警標(biāo)志物
腫瘤血管形成與腫瘤免疫
教學(xué)：
多年主講本科生《醫(yī)學(xué)免疫學(xué)》、《分子生物學(xué)》、《臨床免疫及診斷》，研究生《分子生物學(xué)進(jìn)展》、《高級(jí)免疫學(xué)》。
學(xué)習(xí)經(jīng)歷：
1980—1984：學(xué)士，南開大學(xué)生物系遺傳專業(yè)
1987—1990：碩士，南開大學(xué)分子生物學(xué)研究所生物與分子生物學(xué)專業(yè)
2004—2007：博士，天津醫(yī)科大學(xué)免疫學(xué)專業(yè)
工作經(jīng)歷：
1984—1987：天津醫(yī)科大學(xué)計(jì)劃生育研究所助理研究員
1990—2002 ：天津醫(yī)科大學(xué)醫(yī)學(xué)檢驗(yàn)學(xué)院講師/副教授/碩士生導(dǎo)師
2002—2003：美國(guó)密歇根大學(xué)腫瘤研究中心研究員
2003—2010：天津醫(yī)科大學(xué)免疫學(xué)教授/碩士生和博士生導(dǎo)師
2004—2010：美國(guó)匹茲堡大學(xué)醫(yī)學(xué)院病理系研究員
2011—2016：廣西醫(yī)科大學(xué)特聘教授，“長(zhǎng)壽與老年相關(guān)疾病”教育部重點(diǎn)實(shí)驗(yàn)室副主任/教授；轉(zhuǎn)化醫(yī)學(xué)研究中心副主任/教授
2015—至今：廣西南寧市特聘專家
2017—至今：南方科技大學(xué)醫(yī)學(xué)院/研究副教授
所獲榮譽(yù)：
2009- Scholar-in-Training Award, AACR
2007- Young Investigator Travel Award, ASBMR
2005- Scholar-in-Training Award, AACR
2003- Second class of Tianjia Technology Progress Award, China
2003- Third class of Tianjin Technology Progress Award, China
2000- Third class of Tianjin Technology Progress Award, China
1997- Third class of Tianjin Technology Progress Award, China
1994- Third class of Xianyi Zhu Medical Award, China
代表文章：
Yun C, Chang M, Hou G, Lan T, Yuan H, Su Z, Zhu D, Liang W, Li Q, Zhu H, Zhang J, Lu Y*, Deng J*, Guo H*. Mangiferin suppresses allergic asthma symptoms by decreased Th9 and Th17 responses and increased Treg response. Molecular Immunology. 2019, 114:233-242.
Guo H, Wang F, Diao Y, Zhang Z, Chen Q, Qian CN, Keller ET, Zhang J*, Lu Y*. Knockdown of Notch1 inhibits nasopharyngeal carcinoma cell growth and metastasis via downregulation of CCL2, CXCL16, and uPA. Molecular Carcinogenesis. 2019, 58:1886-1896.
Liang W, Wang F, Chen Q, Dai J, Escara-Wilke J, Keller ET, Zimmermann J, Hong N, Lu Y*, Zhang J*. Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone. J Cancer Res Clin Oncol. 2019 Jun 6. 145:1999-2012. Doi: 10.1007/s00432-019-02950-y.
Wang W, Yang X, Dai J, Lu Y, Zhang J, and Keller E*. Prostate cancer promotes a vicious cycle of bone metastasis progression through inducing osteocytes to secrete GDF15 that stimulates prostate cancer growth and invasion. Oncogene, 2019, Feb 12. 38（23）：4540-45559. doi: 10.1038/s41388-019-0736-3
Su W, Wang L, Niu F, Zou L, Guo C, Wang Z, Yang X, Wu J, Lu Y, Zhang J, Beer DG, Yang Z, Chen G. LINC00857 knockdown inhibits cell proliferation and induces apoptosis via involving STAT3 and MET oncogenic proteins in esophageal adenocarcinoma. Aging-US. 2019 May 13;11(9):2812-2821. doi: 10.18632/aging.101953.
Junlin Shi, Lihui Wang, Chunlin Zou, Yudui Xia, Siyuan Qin, Evan Keller, Atsushi Mizokami, Jian Zhang*, Yi Lu*. Tumor microenvironment promotes prostate cancer cell dissemination via the Akt/mTOR pathway. Oncotarget, 2018, 9(10):9206-18.
Xia Y, Liu X, Zou C, Feng S, Guo H, Yang Y, Lei Y, Zhang J*, and Lu Y*. Garcinone C exerts antitumor activity by modulating the expression of ATR/Stat3/4E?BP1 in nasopharyngeal carcinoma cells. Oncology Reports, 2018, 39:1485-93.
Jie Meng, Li-Hui Wang, Chun-Lin Zou, Sheng-Ming Dai, Jian Zhang*, Yi Lu*. C10orf116 Gene Copy Number Loss in Prostate Cancer: Clinicopathological Correlations and Prognostic Significance. Med Sci Monit 2017; 23:5176-5183. DOI: 10.12659/MSM.906680.
Pascal LE, Masoodi KZ, Liu J1, Qiu X, Song Q, Wang Y, Zang Y, Yang T, Wang Y, Rigatti LH, Chandran U, Colli LM, Vencio RZN, Lu Y, Zhang J, Wang Z. Conditional deletion of ELL2 induces murine prostate intraepithelial neoplasia. J Endocrinol. 2017 Nov;235(2):123-136. doi: 10.1530/JOE-17-0112.
Chunlin Zou, Yi Lu, Xiahong Teng, Shuyan Wang, Xiaoting Sun, Fen Huang, Guannan Shu, Xin Huang, Hongwei Guo, Zhiguo Chen, Jian Zhang, Yu Alex Zhang. MRI tracking of autologous pancreatic progenitor-derived insulin-producing cells in monkeys. Rep. 2017, 7(1):2505.
Wenchu Wang, Lihui Wang, Atsushi Mizokami, Junlin Shi, Chunlin Zou, Jinlu Dai, Evan T. Keller, Yi Lu* and Jian Zhang*. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling. Chinese Journal of Cancer, 2017; 36:35
Yong Lei, Yanhua Yi, Yang Liu, Xia Liu, Evan T. Keller, Chao-Nan Qian, Jian ZhangZ* and Lu Y*. Metformin targets multiple signaling pathways in cancer. Chinese Journal of Cancer, 2017, 36 (1):17.
Qiuyan Chen, Siyuan Qin, Yang Liu, Minghuang Hong, Chao-Nan Qian, Evan T Keller, Zhang J, Lu Y*. IGFBP-6 is a novel nasopharyngeal carcinoma prognostic biomarker. Oncotarget, 2016， Oct 18;7(42):68140-68150.
Jing Li, Xin Yang, Hao Guan, Atsushi Mizokami, Evan T. Keller, Xiaozhen Xu, Xia Liu, Jiyong Tan, Longyuan Hu, Lu Y*, Jian Zhang. Exosome-derived microRNAs contribute to prostate cancer chemoresistance. International Journal of Oncology, 2016，49:838-846.
Guihui Qin, Min Luo, Junze Chen, Yiwu Dang, Gang Chen, Li Li, Jing Zeng, Lu Y, Jie Yang. Reciprocal activation between MMP-8 and TGF-β1 stimulates EMT and malignant progression of hepatocellular carcinoma. Cancer Letters, 2016 Apr 28;374(1):85-95. doi: 10.1016/j.canlet.2016.02.001.
Yu Zhu, Chunlin Zou, Zhe Zhang, Chaonan Qian, Xin Yang, Junlin Shi, Yudui Xia, Zhang J, Lu Y*. MEK inhibitor diminishes nasopharyngeal carcinoma (NPC) cell growth and NPC-induced osteoclastogenesis via modulating CCL2 and CXCL16 expression. Tumor Biology, 2015, 36(11):8811-8. doi: 10.1007/s13277-015-3595-8.
Sha He, Lu Y, Xia Liu, Xin Huang, Evan Keller, Chao-Nan Qian, Zhang Wnt3a: function and implication in cancer. Chinese Journal of Cancer, 2015, 34(3):50. DOI: 10.1186/s40880-015-0052-4
Hongwei Guo, Xiaolin Zhou, Lu Y, Liye Xie, Qian Chen, Evan T. Keller, Qian Liu, Qinghua Zhou , and Zhang Translational progress on tumor biomarkers. Thoracic Cancer. 27 JUL 2015, DOI: 10.1111/1759-7714.12294
Huajiao Guo, Lu Y, Jianhua Wang, Xia Liu, Evan T. Keller, Qian Liu, Qinghua Zhou, Jian Zhang, Targeting Notch Signaling Pathway in Cancer Therapeutics. Thoracic Cancer, 2014, 5. 473-86 .
Lu Y, Gu X, Chen L, Yao Z, Song J, Niu X, Xiang R, Cheng T, Qin Z, Deng W, Li LY. Interferon-γ produced by tumor-infiltrating NK cells and CD4+ T cells downregulates TNFSF15 expression in vascular endothelial cells. Angiogenesis. 2014 Jul;17(3):529-40.
Lu Y, Zhang Z, Yan Z, Chen L, Deng W, Lotze M, Wang Z, Lin X, Li LY. Restoration of p53 Functions in Breast Cancer Cells in vivo with Recombinant GnRH-p53 Fusion Protein Enhances 5-Fluorouracil Anticancer Efficacy. Apoptosis， Oct;18(10):1214-23，
Zhang J, Lu Y, and Pienta KJ. Multiple roles of CC chemokine ligand 2 (CCL2) in promoting prostate cancer growth. J National Cancer Institute 102(8):522-8, 2010.
Lu Y*, Chen Q, Corey E, Xie W, Fan J, Mizokami A, and Zhang J. Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone. Clin Exp Metastasis 26(2):161-9, 2009.
Lu Y, Nie DB, Witt WT, Chen Q, Shen M, Xie H, Lai L, Dai Y, Zhang J. Expression of fat-1 gene diminishes prostate cancer growth in vivo through enhancing apoptosis and inhibiting GSK-3β phosphorylation. Molecular Cancer Therapeutics 7(10):3203-11,
Lu Y, Cai Z, Xiao G, Keller ET, Mizokami A, Yao Z, Roodman GD, Zhang J. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Cancer Res 67:3646-53, 2007.
Lu Y, Xiao G, Galson DL, Nishio Y, Mizokami A, Yao Z, and Zhang J. PTHrP-induced MCP-1 production by human bone marrow endothelial cells promotes osteosteoclastast differentiation and prostate cancer cell proliferation and invasion in vitro. Int J of Cancer 121:724-733, 2007.
Lu Y, Cai Z, Galson DL, Xiao G, Liu YL, George D, Melhem MF, Yao Z and Zhang J. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for PCa growth and invasion. Prostate 66:1311-8, 2006.